Athersys teams with Chugai Pharmaceutical to develop cell therapy in Japan

Story excerpt provided by Crain’s Cleveland Business.

Cleveland biotech company Athersys Inc. (Nasdaq: ATHX) said it has formed a partnership and licensing agreement with Chugai Pharmaceutical Co. (Tokyo Stock Exchange: 4519) to develop and commercialize Athersys’ MultiStem cell therapy for ischemic stroke in Japan.

Click here to read the complete article.

Originally published March 2, 2015.